Andrew Cooper
Stock Analyst at Raymond James
(3.04)
# 1,250
Out of 5,156 analysts
151
Total ratings
44.03%
Success rate
0.06%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $23.13 | +94.55% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $85.38 | +11.27% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $75.59 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $8.15 | +96.32% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $64.23 | +21.44% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $91.20 | -33.11% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $92.11 | +24.85% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $509.97 | +4.91% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.81 | +107.90% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $14.88 | +68.01% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $215.00 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $198.80 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $103.71 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.74 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $205.22 | -58.58% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $19.86 | +282.68% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.36 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.92 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.37 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.20 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $23.13
Upside: +94.55%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $85.38
Upside: +11.27%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $75.59
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $8.15
Upside: +96.32%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $64.23
Upside: +21.44%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $91.20
Upside: -33.11%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $92.11
Upside: +24.85%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $509.97
Upside: +4.91%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.81
Upside: +107.90%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $14.88
Upside: +68.01%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $215.00
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $198.80
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $103.71
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $17.74
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $205.22
Upside: -58.58%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $19.86
Upside: +282.68%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.36
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.92
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.37
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.20
Upside: -